- 米国企業
- Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DEVRDN
| 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 |
---|
Cash and cash equivalents | - | - | - | - | - | 25 | 46 | 42 | 156 | 103 |
---|
Short-term investments | - | - | - | - | - | - | - | - | 269 | 375 |
---|
Prepaid expenses and other current assets | 0 | 321,000 | 0 | 3 | 3 | 3 | 2 | 3 | 7 | 9 |
---|
Unbilled revenue - related party | - | - | - | - | - | - | - | - | 0 | 0 |
---|
Total current assets | 7 | 12 | 4 | 52 | 65 | 30 | 130 | 200 | 431 | 486 |
---|
Property and equipment, net | 1 | 1 | - | 1 | 1 | 1 | 0 | 0 | 1 | 2 |
---|
Operating lease right-of-use asset | - | - | - | - | - | - | 0 | 2 | 2 | 2 |
---|
Other assets | - | - | - | 0 | 0 | - | 1 | 1 | 1 | 1 |
---|
Total assets | 8 | 13 | 4 | 52 | 66 | 30 | 131 | 204 | 435 | 490 |
---|
Accounts payable | 0 | 242,000 | 0 | 1 | 1 | 1 | 1 | 2 | 14 | 2 |
---|
Accrued Liabilities, Current | 0 | 1 | 3 | 3 | 4 | 5 | 10 | 11 | 19 | 24 |
---|
Contract with Customer, Liability, Current | - | - | - | - | - | - | 0 | - | 0 | 0 |
---|
Total current liabilities | 2 | 2 | 5 | 4 | 7 | 10 | 11 | 14 | 33 | 27 |
---|
Long-Term Debt | - | - | - | - | - | - | - | - | 5 | 20 |
---|
Deferred revenue - related party | - | - | - | - | - | - | - | - | 1 | 1 |
---|
Other liabilities | 0 | 24,000 | - | 0 | 0 | - | 1 | 1 | 1 | 1 |
---|
Total liabilities | - | - | - | 14 | 15 | 15 | 11 | 16 | 40 | 48 |
---|
Series A Preferred Stock | - | - | - | - | - | - | 181 | 118 | 85 | 78 |
---|
Series B Preferred Stock | - | - | - | - | - | - | - | 16 | 57 | 128 |
---|
Preferred stock | - | - | - | - | - | - | - | - | - | - |
---|
Common Stock, Value, Issued | 0 | 106,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
---|
Additional paid-in capital | 13 | 28 | 30 | 132 | 177 | 184 | 218 | 412 | 741 | 961 |
---|
Accumulated other comprehensive gain (loss) | - | - | - | - | -0 | - | -0 | -0 | -0 | 0 |
---|
Accumulated deficit | -7 | -17,968,000 | -31 | -94 | -126 | -168 | -279 | -358 | -488 | -726 |
---|
Series A Preferred Stock | - | - | - | - | - | - | 181 | 118 | 85 | 78 |
---|
Series B Preferred Stock | - | - | - | - | - | - | - | 16 | 57 | 128 |
---|
Total stockholders’ equity | 6 | 10 | -0 | 39 | 51 | 16 | 120 | 188 | 395 | 442 |
---|
Total liabilities and stockholders’ equity | 8 | 13 | 4 | 52 | 66 | 30 | 131 | 204 | 435 | 490 |
---|